Primary central nervous system lymphoma (PCNSL) is an aggressive diffuse large B-cell lymphoma in the brain, spinal cord, eyes, or cerebrospinal fluid. When first-line methotrexate-based therapy achieves remission, doctors face another challenge: a relapse risk that stays high for years. Most relapses are only found after patients report symptoms.
Studies show up to 60% of PCNSL patients relapse after initial therapy, according to a review of relapsed and refractory disease published via PMC. A separate clinical analysis published via PMC found that 66.1% of those relapses occur within the first two years after diagnosis. This concentration of risk in a narrow window means surveillance schedules that slip by even a few weeks matter.
Most neuro-oncology practices understand this relapse risk. The real problem is operational: getting the MRI at the right time, making sure the radiology report reaches the doctor, and putting findings from ophthalmology, neurology, and lab work in one place where the doctor can see them all.
The Relapse Window That Drives Surveillance Decisions
PCNSL carries one of the highest relapse rates among diffuse large B-cell lymphomas. The central nervous system acts as a safe place for cancer cells, limiting how well systemic monitoring works for other lymphoma types. Brain MRI is the main tool for watching patients after remission. Eye exams are added for patients with intraocular disease at diagnosis, and cerebrospinal fluid (CSF) testing is used when leptomeningeal involvement is suspected.
A prospective imaging analysis of the ANOCEF-GOELAMS randomized trial, published via PMC, found that PCNSL relapses most often occur at the original tumor site or in new brain locations. Leptomeningeal and spinal relapse happen less often but remain a risk for some patients. This variation means a single, fixed surveillance plan does not work the same for all patients. The imaging plan needs to match each patient's original disease location and how they responded to first-line treatment.
What Structured Surveillance MRI Does and Does Not Catch
The medical community has not agreed on a single imaging protocol after remission. The EHA-ESMO Clinical Practice Guideline, accessible via PMC, recommends brain imaging at least every three months for two years after therapy ends, then every six months for three more years, and annually after that. It notes that structured imaging makes sense for patients who could still get curative re-treatment, given how many relapses happen in the first two years.
A study designed to set an MRI protocol for PCNSL, published via PMC, found that structured surveillance worked best in the first year after diagnosis. In that year, 48.3% of relapses showed up on scheduled imaging. Across the whole surveillance window, only about 20% of all PCNSL relapses were caught on scheduled MRI. Most relapses came to light when patients reported symptoms and got unscheduled imaging.
That 20% figure needs careful interpretation. It does not mean routine surveillance is optional. Asymptomatic relapse found on a scheduled scan is usually smaller, allows more treatment options, and is caught before the patient loses function. But the data shows that scheduled imaging and symptom-driven imaging work together, not as substitutes. A surveillance system needs to track both in the same patient record so the doctor can see the full picture of disease over time.
Where Coordination Breaks Down in Practice
In real clinical practice, post-remission PCNSL surveillance involves handoffs across many departments. Neuro-oncology or hematology-oncology manages treatment. Radiology performs and interprets the MRI. Ophthalmology checks for intraocular relapse. The neuro-oncologist or a neurologist may order CSF testing when needed. Each department typically has its own way of scheduling, reporting results, and flagging important findings.
This creates multiple points where things can go wrong. A surveillance MRI gets done, but the radiology report stays in their system and never reaches the oncologist. An ophthalmology note about early eye changes does not show up in the neuro-oncology team's records. A surveillance appointment shifts five or six weeks because the scanner is busy, with no record of the change and no adjustment to the next appointment to make up for it.
These are structural problems, not individual mistakes. Research on why test results get missed in clinical practice, published via PMC, found that missing EHR alerts are a big cause. Results end up in trainee inboxes instead of the attending's. If the doctor who ordered the test leaves the service, no one follows up. Findings get missed or found by accident. PCNSL patients in long-term follow-up are especially at risk. Their care team may change multiple times across a five-year or longer surveillance period.
Multi-Department Silos and the PCNSL Surveillance Record
Intraocular PCNSL adds an important surveillance element that most general EHR systems do not handle well. A meaningful number of PCNSL cases have intraocular involvement at diagnosis, and patients without eye disease at first may develop it later. Eye surveillance follows a different schedule than brain MRI and is done by different specialists, often in a separate clinic or affiliated facility.
When the neuro-oncologist cannot access the ophthalmology note, and when the ophthalmologist has not seen the latest MRI report, both doctors are making decisions with incomplete information. The problem is structural. The scheduling systems do not connect. The patient record does not show cross-department findings in one place. No automatic alert tells anyone when the eye appointment happened eight weeks later than the protocol said it should.
CSF testing, ordered when leptomeningeal relapse is suspected, adds a third data source. Lab results stay in the lab system, separate from both the MRI timeline and the eye visit history. The doctor piecing together the full picture of disease status has to check three separate systems, each with separate logins, formats, and alerts. That manual work takes time most oncologists do not have between patients.
Closing the Gap With a Coordinated Oncology Platform
Fixing these coordination problems does not require changing clinical protocol. It requires connecting the data that already exists.
An oncology system built for structured surveillance can track when each PCNSL patient should have imaging after remission, alert when a scheduled scan is overdue, and display the radiology report, eye exam notes, and the latest CSF result together in one patient timeline. When a patient gets an unscheduled MRI because of a new headache or memory problem, the system adds that report and places it in the right spot in the surveillance record. Doctors see all the scans in one place, not scattered across separate systems.
Smart interval tracking also stops schedule drift. If a six-month MRI is scheduled for seven months because the scanner is busy, the system records the change and adjusts the next appointment to stay on track. This prevents the schedule from drifting further out. It is the kind of operational detail that gets lost when surveillance depends on paper or calendar entries spread across departments.
For care teams managing PCNSL patients alongside a hospital neuro-oncology service, a shared system means all providers see the same information without requiring a fax, forwarded PDF, or phone call to find the last MRI report. An integrated system extracts findings from radiology reports as they arrive and places them in the patient timeline. For similar operational challenges in other brain tumor contexts, the post-resection surveillance approach described in Closing MRI Surveillance Gaps After Glioblastoma Resection applies the same interval-tracking principles to post-remission follow-up. If your clinic also manages systemic lymphoma patients in active treatment, Why Lymphoma Mid-Treatment Re-Staging Intervals Slip covers the scheduling patterns that cause comparable drift in that setting.
Demos take 30 minutes. We will walk you through this article's surveillance workflow using your clinic's patient types and scheduling constraints. Book a demo to see how a system tracks post-remission imaging cadence across neuro-oncology, radiology, and ophthalmology without adding work for your team.